Filter Results:
(617)
Show Results For
- All HBS Web
(617)
- People (2)
- News (54)
- Research (446)
- Events (2)
- Multimedia (8)
- Faculty Publications (391)
Show Results For
- All HBS Web
(617)
- People (2)
- News (54)
- Research (446)
- Events (2)
- Multimedia (8)
- Faculty Publications (391)
- September 2008
- Background Note
Background on the Technology of Molecular Diagnostics
By: Regina E. Herzlinger and Jason Sanders
To be used as background reading for the "EXACT Sciences Corp.: Commercializing a Diagnostic Test" and "Diagnostic Genomics" cases, HBS nos. 308-090 and 309-040. View Details
Herzlinger, Regina E., and Jason Sanders. "Background on the Technology of Molecular Diagnostics." Harvard Business School Background Note 309-050, September 2008.
- 01 Dec 1996
- News
Entrepreneurship at HBS
direct marketing, consumer products, and consulting. Following Professor Georges F. Doriot's lead, our graduates have had a major impact on the venture capital industry, which in turn financed a revolution in semiconductors, personal computers, communications, and... View Details
- 11 Sep 2007
- First Look
First Look: September 11, 2007
and deliverables. Many critical business challenges are detailed in this case. Nevertheless, given their fully integrated business model and significant manufacturing base, the odds are in Biocon's favor to overcome these challenges and lead India's View Details
Keywords: Martha Lagace
- 22 Sep 2009
- First Look
First Look: September 22
biotechnology company, launches a program to develop therapies for neglected diseases (e.g., malaria, TB), giving away the intellectual property. This case focuses on the decision of which diseases, which partnerships, and which markets... View Details
Keywords: Martha Lagace
- 13 Jun 2005
- Research & Ideas
From Turf Wars to Learning Curves: How Hospitals Adopt New Technology
in many cases, perform identical procedures in two or more hospitals during the course of a given week. We have found that this movement has negative effects on the degree to which surgeons are able to leverage their prior experience to improve future performance. We... View Details
- September 2009 (Revised December 2009)
- Supplement
Genzyme Center (B)
By: Michael W. Toffel and Aldo Sesia
Genzyme Corporation is in the midst of planning its new corporate headquarters, which incorporates many innovative green building features. After learning that the building as planned would likely earn a LEED Silver rating, an intermediate score in the LEED green... View Details
Keywords: Environmental Sustainability; Corporate Social Responsibility and Impact; Standards; Cost vs Benefits; Biotechnology Industry; Biotechnology Industry; Biotechnology Industry; Biotechnology Industry
Toffel, Michael W., and Aldo Sesia. "Genzyme Center (B)." Harvard Business School Supplement 610-009, September 2009. (Revised December 2009.)
- September 2012 (Revised September 2012)
- Course Overview Note
Building Life Science Businesses Fall 2012: Course Outline and Syllabus
This Course Outline and Syllabus gives an overview of the Fall 2012 class Building Life Science Businesses View Details
- 11 Nov 2015
- Working Paper Summaries
Public R&D Investments and Private-sector Patenting: Evidence from NIH Funding Rules
- 24 Sep 2007
- Research & Ideas
The FDA: What Will the Next 100 Years Bring?
The U.S. Food and Drug Administration, which was created by the passage of the 1906 Federal Food and Drugs Act, regulates companies and industries accounting for one-quarter of all consumer spending, roughly $1.5 trillion worth of consumer goods and medicines. It... View Details
- 1997
- Chapter
Patent Scope and Emerging Industries: Biotechnology, Software, and Beyond
By: Josh Lerner and Robert P. Merges
Keywords: Patents; Applications and Software; Genetics; Biotechnology Industry; Biotechnology Industry
Lerner, Josh, and Robert P. Merges. "Patent Scope and Emerging Industries: Biotechnology, Software, and Beyond." In Competing in the Age of Digital Convergence, edited by D. B. Yoffie, 301–324. Boston: Harvard Business School Press, 1997.
- 05 Aug 2014
- First Look
First Look: August 5
Case 614-063 Merrimack Pharmaceuticals, Inc. (A) In 2006, Merrimack Pharmaceuticals was a fast-growing biotechnology company. Its leadership team was divided over whether to keep R&D organized in functional departments or transition... View Details
Keywords: Sean Silverthorne
- 01 Oct 2000
- News
The Entrepreneurial Venture
surprising that the venture capital industry was essentially dormant at the time. But with the growth of the microprocessor and of biotechnology in the late 1970s, as well as the deregulation of the airline and financial services... View Details
- 01 Sep 2011
- News
Green Day
good ROI.” Diniz began to brainstorm with Paulo Puterman, a friend studying to get his PhD in biotechnology at the University of São Paulo who also happened to be focused on the highly efficient elephant grass/electricity equation. “After... View Details
- 17 Oct 2012
- Research & Ideas
America Needs a Manufacturing Renaissance
innovation process, but it is not the whole thing. Innovation is about moving the idea from concept to the customer's hands. For some highly complex products (flat-panel displays, PV cells, and biotechnology drugs, to name a few) the... View Details
- September 1989 (Revised December 1989)
- Case
Beef Hormone Trade Dispute
By: Ray A. Goldberg
Keywords: Trade; Agribusiness; Food; Biotechnology Industry; Biotechnology Industry; Biotechnology Industry
Goldberg, Ray A. "Beef Hormone Trade Dispute." Harvard Business School Case 590-035, September 1989. (Revised December 1989.)
- July 2013
- Case
Novozymes: Establishing the Cellulosic Ethanol Value Chain
By: Willy Shih and Sen Chai
As the world's largest producer of industrial enzymes, Novozymes had invested heavily for many years to bio-engineer enzymes that could break down cellulose into fermentable sugar. In 2010, the company had launched what it thought would become a breakthrough product... View Details
Keywords: System Complexity; Industrial Enzymes; Ethanol; Collulosic Ethanol; Fermentation; Genomics; Genetic Engineering; Value Chain; Assembling Value Chain; Energy Sources; Renewable Energy; Collaborative Innovation and Invention; Innovation and Management; Innovation Strategy; Technological Innovation; Management; Growth and Development Strategy; Industry Growth; Production; Research; Research and Development; Science; Genetics; Natural Environment; Environmental Sustainability; Science-Based Business; Business Strategy; Commercialization; Vertical Integration; Agriculture and Agribusiness Industry; Biotechnology Industry; Energy Industry; Denmark; United States
Shih, Willy, and Sen Chai. "Novozymes: Establishing the Cellulosic Ethanol Value Chain." Harvard Business School Case 614-001, July 2013.
- 03 Dec 2001
- Research & Ideas
Healthcare Conference Looks At Ailing Industry
Mixing Risk And Reward The basic model that the biotechnology industry has followed for over twenty years is also changing, and for the better, according to panelists at a session titled "Will Equal Biotechnology-Pharma Partnerships... View Details
- 15 Feb 2022
- Blog Post
Health is Wealth | The Path to Creating a Venture
her sleep patterns – to try to improve her performance. It was during this time that she connected with Wallerstofer, who had a PhD in biotechnology and had spent the previous decade building consumer facing nutrition products based on... View Details
- January 2007 (Revised January 2007)
- Background Note
Note on the U.S. Food and Drug Administration
By: Robert F. Higgins, Richard G. Hamermesh and Virginia Fuller
Describes the U.S. FDA with particular emphasis on its role in the development of new drugs, biologic products, and medical devices today. Provides context for the drug approval process by describing the FDA's history and organizational structure. View Details
Keywords: Health; Governance Compliance; Policy; Product Development; Government and Politics; Biotechnology Industry; Biotechnology Industry; Biotechnology Industry; Biotechnology Industry; United States
Higgins, Robert F., Richard G. Hamermesh, and Virginia Fuller. "Note on the U.S. Food and Drug Administration." Harvard Business School Background Note 807-050, January 2007. (Revised January 2007.)
- 26 Sep 2006
- First Look
First Look: September 26, 2006
Danner was about to make his first presentation to the board of directors of Codon Devices, a one-year-old biotechnology start-up based in Cambridge, Massachusetts. After a month as the company's CEO, Danner was prepared to lay out his... View Details
Keywords: Sean Silverthorne